Navigation Links
Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc., announced that the United States Patent and Trademark Office has issued patents that cover CAT-1000 and CAT-2000 series compounds. One patent (U.S. Patent No. 8,173,831) covers the CAT-1000 series' conjugation of salicylate and an omega-3 fatty acid using Catabasis' SMART Linker technology; the compounds in this series are intended to treat diseases involving chronic inflammation such as inflammatory bowel disease and Duchenne muscular dystrophy. CAT-2000 series' patents (U.S. Patent Nos. 8,304,551 and 8,304,552) cover SMART Linker conjugation of niacin and an omega-3 fatty acid. CAT-2003, the series' lead compound, is being tested for patients with severe hypertriglyceridemia. The patents cover composition of matter for both series, including lead products CAT-1004 and CAT-2003, until 2029 and 2030 respectively.

"These patents, along with others in our portfolio, provide multi-layered protection for our SMART Linker conjugates in the CAT-1000 and CAT-2000 series," said Jill Milne , Ph.D., chief executive officer of Catabasis. "The patents validate our unique chemistry platform. We create new compounds, conjugated using our SMART Linker technology, giving us the ability to treat complex human diseases such as inflammatory and metabolic diseases."

About CAT-1004CAT-1004 is a new chemical entity that is a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate. Catabasis' lead program amplifies the beneficial effects of omega-3 fatty acids and salicylate to target inflammation, an underlying cause of many chronic diseases. A growing body of peer-reviewed research, along with clinical experience, has demonstrated important therapeutic benefits of DHA and eicosapentaenoic acid (EPA). Salicylates are anti-inflammatories with proven clinical efficacy and safety, and have been used safely for years to treat inflammatory bowel disease and other diseases of inflammation. Inhibition of NF-kB in muscle satellite cells has been hypothesized to have a beneficial effect in Duchenne muscular dystrophy. Catabasis recently announced positive Phase 1 data for CAT-1004 showing it was safe and well tolerated and that the technology allowed the active components to synergistically inhibit the NF-kB pathway. Phase 2 studies are being planned to evaluate the safety and efficacy of CAT-1004 in patients with inflammatory bowel disease and as a replacement for corticosteroids in patients with Duchenne muscular dystrophy.

About CAT-2003CAT-2003 is a new chemical entity that is a conjugate of the B vitamin niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, linked using the company's proprietary SMART Linker technology. It is being investigated for the treatment of severe hypertriglyceridemia. In preclinical models of severe hypertriglyceridemia, a significant and dose-dependent reduction in plasma triglycerides was observed with CAT-2003, while a simple combination of niacin and omega-3 had only a marginal effect. In preclinical models of dyslipidemia, CAT-2003 dramatically reduced LDL cholesterol. In combination with a statin, CAT-2003 synergistically lowered LDL cholesterol. Because CAT-2003 is not activated until it is delivered inside of the target cell, CAT-2003 is not expected to activate the receptor that causes "niacin flush," a side effect characterized by blushing of the skin and a sensation of warmth resulting from blood vessel dilation; this effect can reduce patient compliance. A Phase 1 study of CAT-2003 is ongoing and data is expected in the second half of 2013.

About CatabasisCatabasis is a clinical-stage company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway to produce new chemical entities with significantly enhanced efficacy and an improved safety and tolerability profile. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit for more information.Media Contacts

Corporate ContactTony Russo, Ph.D.

Amy LynchMatt Middleman, M.D.

Catabasis Pharmaceuticals, Inc.Russo Partners

T: (617)-349-1971T: 212-845-4251


SOURCE Catabasis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
8. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
9. Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
10. Horizon Technology Finance Closes $2 Million Venture Loan Facility with New Haven Pharmaceuticals
11. Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 3D bioprinting market ... according to a new report by Grand View Research Inc. ... (CKD) which demands kidney transplantation is expected to boost the ... substitute for organ transplantation. --> 3D bioprinting market ... according to a new report by Grand View Research Inc. ...
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):